GlassScriptPhysician profile
Silvia Huebner
NPI 1295711620
$14,357.12
in general payments reported to CMS, 2019-2025
31 companies · $2,550 in 2025
The $2,550 reported for 2025 was more than what 76% of Allergy providers received nationally (typical 2025 total: $1,129).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,301 · 2020: $1,380 · 2021: $2,414 · 2022: $2,432 · 2023: $2,239 · 2024: $2,041 · 2025: $2,550.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,730 · Education: $72.53 · Consulting Fee: $26.79.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,730.21 |
| Education | $72.53 |
| Consulting Fee | $26.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $3,623.88 | 2019-2025 | Fasenra, Tezspire, Breztri |
| Csl Behring | $2,496.31 | 2019-2025 | Hizentra, Haegarda, Andembry |
| Glaxosmithkline, LLC. | $1,041.69 | 2019-2025 | Nucala |
| Genzyme Corporation | $886.57 | 2019-2025 | |
| Grifols USA, LLC | $727.60 | 2019-2025 | Xembify, Prolastin-C Liquid |
| Novartis Pharmaceuticals Corporation | $705.83 | 2019-2025 | |
| Pharming Healthcare, INC. | $625.39 | 2020-2023 | Ruconest |
| Boehringer Ingelheim Pharmaceuticals, INC. | $533.78 | 2019-2023 | Spiriva Respimat |
| Regeneron Healthcare Solutions, INC. | $502.05 | 2019-2025 | Dupixent |
| Optinose US, INC. | $496.63 | 2019-2025 | |
| Pfizer INC. | $476.64 | 2019-2025 | |
| Amgen INC. | $460.75 | 2021-2025 | Tezspire |
| Takeda Pharmaceuticals U.S.A., INC. | $438.94 | 2020-2025 | Takhzyro, Eohilia, Cuvitru |
| Genentech USA, INC. | $250.66 | 2019-2025 | Xolair |
| Kaleo, INC. | $233.23 | 2019-2021 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bio Products Laboratory USA, INC. | $175.65 | 2021-2023 | Gammaplex, Coagadex |
| Teva Pharmaceuticals USA, INC. | $159.61 | 2019-2023 | Cinqair |
| Incyte Corporation | $75.45 | 2022-2025 | Opzelura |
| Ars Pharmaceuticals Operations, INC. | $69.09 | 2025 | Neffy |
| Biocryst US Sales Co., LLC | $54.80 | 2021-2025 | Orladeyo |
| Merck Sharp & Dohme LLC | $48.58 | 2021-2023 | |
| Alk-Abello, INC | $42.63 | 2020-2021 | |
| Octapharma USA, INC. | $40.15 | 2023-2024 | Octagam Immune Globulin (Human), Cutaquig |
| Blueprint Medicines Corporation | $35.82 | 2023-2024 | Ayvakit |
| Biocryst Pharmaceuticals, INC. | $34.93 | 2020 | |
| Hikma Pharmaceuticals USA | $29.52 | 2023-2025 | Ryaltris |
| Adma Biomanufacturing LLC | $26.79 | 2025 | |
| Shire North American Group INC | $19.62 | 2019 | |
| Lilly USA, LLC | $18.26 | 2025 | Ebglyss |
| Leo Pharma INC. | $14.65 | 2022 | |
| Circassia INC. | $11.62 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Silvia Huebner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.